World J Mens Health.  2016 Aug;34(2):89-100. 10.5534/wjmh.2016.34.2.89.

Modifying Risk Factors in the Management of Erectile Dysfunction: A Review

• DeLay KJ
• Haney N
• Hellstrom

• KMID: 2349845
• DOI: http://doi.org/10.5534/wjmh.2016.34.2.89

Abstract

Erectile dysfunction (ED) is prevalent among men and its presence is often an indicator of systemic disease. Risk factors for ED include cardiovascular disease, hypertension, diabetes mellitus (DM), tobacco use, hyperlipidemia, hypogonadism, lower urinary tract symptoms, metabolic syndrome, and depression. Addressing the modifiable risk factors frequently improves a patient's overall health and increases lifespan. The literature suggests that smoking cessation, treatment of hyperlipidemia, and increasing physical activity will improve erectile function in many patients. How the treatment of DM, depression, and hypogonadism impacts erectile function is less clear. Clinicians need to be aware that certain antihypertensive agents can adversely impact erectile function. The treatment of men with ED needs to address the underlying risk factors to ameliorate the disease process.

Keyword

Erectile dysfunction; Hypogonadism; Risk reduction behavior

MeSH Terms

Antihypertensive Agents
Cardiovascular Diseases
Depression
Diabetes Mellitus
Erectile Dysfunction*
Humans
Hyperlipidemias
Hypertension
Hypogonadism
Lower Urinary Tract Symptoms
Male
Motor Activity
Risk Factors*
Risk Reduction Behavior
Smoking Cessation
Tobacco Use
Antihypertensive Agents

Figure

• 

  Fig. 1 The pathophysiological connection between the metabolic syndrome and erectile dysfunction.

Reference

1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84:50–56. PMID: 10444124.

2. Rosen RC, Wing R, Schneider S, Gendrano N 3rd. Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. Urol Clin North Am. 2005; 32:403–417. PMID: 16291033.

3. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000; 163:460–463. PMID: 10647654.

4. Hyde Z, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA, et al. Prevalence and predictors of sexual problems in men aged 75-95 years: a population-based study. J Sex Med. 2012; 9:442–453. PMID: 22145992.

5. Martin SA, Atlantis E, Lange K, Taylor AW, O'Loughlin P, Wittert GA, et al. Predictors of sexual dysfunction incidence and remission in men. J Sex Med. 2014; 11:1136–1147. PMID: 24548342.

6. Jackson G. The importance of risk factor reduction in erectile dysfunction. Curr Urol Rep. 2007; 8:463–466. PMID: 18042325.

7. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011; 171:1797–1803. PMID: 21911624.

8. Horasanli K, Boylu U, Kendirci M, Miroglu C. Do lifestyle changes work for improving erectile dysfunction? Asian J Androl. 2008; 10:28–35. PMID: 18087641.

9. Bivalacqua TJ, Musicki B, Usta MF, Champion HC, Kadowitz PJ, Burnett AL, et al. Endothelial nitric oxide synthase gene therapy for erectile dysfunction. Curr Pharm Des. 2005; 11:4059–4067. PMID: 16378511.

10. Safarinejad MR, Hosseini S. Erectile dysfunction: clinical guidelines (1). Urol J. 2004; 1:133–147. PMID: 17914678.

11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227–239. PMID: 15249516.

12. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male. 2008; 11:193–199. PMID: 19172551.

13. Kaya E, Sikka SC, Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med. 2015; 12:856–875. PMID: 25675988.

14. Nunes KP, Labazi H, Webb RC. New insights into hypertension-associated erectile dysfunction. Curr Opin Nephrol Hypertens. 2012; 21:163–170. PMID: 22240443.

15. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006; 97(Suppl 2):23–28. discussion 44-5. PMID: 16507050.

16. Behr-Roussel D, Gorny D, Mevel K, Compagnie S, Kern P, Sivan V, et al. Erectile dysfunction: an early marker for hypertension? A longitudinal study in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2005; 288:R276–R283. PMID: 15297263.

17. Cordero A, Bertomeu-Martínez V, Mazón P, Fácila L, González-Juanatey JR. Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension. Postgrad Med. 2010; 122:51–56. PMID: 21084782.

18. Sasaki H, Yamasaki H, Ogawa K, Nanjo K, Kawamori R, Iwamoto Y, et al. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract. 2005; 70:81–89. PMID: 16126126.

19. El-Sakka AI, Tayeb KA. Erectile dysfunction risk factors in noninsulin dependent diabetic Saudi patients. J Urol. 2003; 169:1043–1047. PMID: 12576842.

20. Malavige LS, Jayaratne SD, Kathriarachchi ST, Sivayogan S, Fernando DJ, Levy JC. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med. 2008; 5:2125–2134. PMID: 18624974.

21. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology. 2004; 64:1196–1201. PMID: 15596196.

22. Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, Park TS, et al. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med. 2006; 23:198–203. PMID: 16433719.

23. Siu SC, Lo SK, Wong KW, Ip KM, Wong YS. Prevalence of and risk factors for erectile dysfunction in Hong Kong diabetic patients. Diabet Med. 2001; 18:732–738.

24. Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E, et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care. 1998; 21:1973–1977. PMID: 9802753.

25. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002; 25:284–291. PMID: 11815497.

26. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia. 1980; 18:279–283. PMID: 7418954.

27. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mc-Kinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151:54–61. PMID: 8254833.

28. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF, et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care. 2003; 26:1093–1099. PMID: 12663579.

29. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998; 338:1397–1404. PMID: 9580646.

30. Binmoammar TA, Hassounah S, Alsaad S, Rawaf S, Majeed A. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. JRSM Open. 2016; 7:2054270415622602. PMID: 26981254.

31. Defeudis G, Gianfrilli D, Di Emidio C, Pofi R, Tuccinardi D, Palermo A, et al. Erectile dysfunction and its management in patients with diabetes mellitus. Rev Endocr Metab Disord. 2015; DOI: 10.1007/s11154-015-9321-4. [Epub].

32. Wessells H, Penson DF, Cleary P, Rutledge BN, Lachin JM, McVary KT, et al. Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol. 2011; 185:1828–1834. PMID: 21420129.

33. Wilson SK, Carson CC, Cleves MA, Delk JR 2nd. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 1998; 159:1537–1539. discussion 1539-40. PMID: 9554349.

34. Bishop JR, Moul JW, Sihelnik SA, Peppas DS, Gormley TS, McLeod DG. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol. 1992; 147:386–388. PMID: 1732600.

35. Peluffo G, Calcerrada P, Piacenza L, Pizzano N, Radi R. Superoxide-mediated inactivation of nitric oxide and peroxynitrite formation by tobacco smoke in vascular endothelium: studies in cultured cells and smokers. Am J Physiol Heart Circ Physiol. 2009; 296:H1781–H1792. PMID: 19363134.

36. Xie Y, Garban H, Ng C, Rajfer J, Gonzalez-Cadavid NF. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat. J Urol. 1997; 157:1121–1126. PMID: 9072555.

37. Huang YC, Chin CC, Chen CS, Shindel AW, Ho DR, Lin CS, et al. Chronic cigarette smoking impairs erectile function through increased oxidative stress and apoptosis, decreased nNOS, endothelial and smooth muscle contents in a rat model. PLoS One. 2015; 10:e0140728. PMID: 26491965.

38. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993; 88:2149–2155. PMID: 8222109.

39. Shaarawy M, Mahmoud KZ. Endocrine profile and semen characteristics in male smokers. Fertil Steril. 1982; 38:255–257. PMID: 6809501.

40. Dorey G. Is smoking a cause of erectile dysfunction? A literature review. Br J Nurs. 2001; 10:455–465. PMID: 12070390.

41. Wu C, Zhang H, Gao Y, Tan A, Yang X, Lu Z, et al. The association of smoking and erectile dysfunction: results from the Fangchenggang Area Male Health and Examination Survey (FAMHES). J Androl. 2012; 33:59–65. PMID: 21436308.

42. Ghalayini IF, Al-Ghazo MA, Al-Azab R, Bani-Hani I, Matani YS, Barham AE, et al. Erectile dysfunction in a Mediterranean country: results of an epidemiological survey of a representative sample of men. Int J Impot Res. 2010; 22:196–203. PMID: 20090762.

43. Chew KK, Bremner A, Stuckey B, Earle C, Jamrozik K. Is the relationship between cigarette smoking and male erectile dysfunction independent of cardiovascular disease? Findings from a population-based cross-sectional study. J Sex Med. 2009; 6:222–231. PMID: 18761596.

44. Austoni E, Mirone V, Parazzini F, Fasolo CB, Turchi P, Pescatori ES, et al. Smoking as a risk factor for erectile dysfunction: data from the Andrology Prevention Weeks 2001-2002 a study of the Italian Society of Andrology (s.I.a.). Eur Urol. 2005; 48:810–817. discussion 817-8. PMID: 16202509.

45. Natali A, Mondaini N, Lombardi G, Del Popolo G, Rizzo M. Heavy smoking is an important risk factor for erectile dysfunction in young men. Int J Impot Res. 2005; 17:227–230. PMID: 15510183.

46. Gades NM, Nehra A, Jacobson DJ, McGree ME, Girman CJ, Rhodes T, et al. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol. 2005; 161:346–351. PMID: 15692078.

47. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A prospective study of risk factors for erectile dysfunction. J Urol. 2006; 176:217–221. PMID: 16753404.

48. Guay AT, Perez JB, Heatley GJ. Cessation of smoking rapidly decreases erectile dysfunction. Endocr Pract. 1998; 4:23–26. PMID: 15251760.

49. Pourmand G, Alidaee MR, Rasuli S, Maleki A, Mehrsai A. Do cigarette smokers with erectile dysfunction benefit from stopping?: a prospective study. BJU Int. 2004; 94:1310–1313. PMID: 15610111.

50. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol. 2004; 43:1405–1411. PMID: 15093875.

51. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001; 104:376–379. PMID: 11468195.

52. Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med. 2014; 11:1626–1635. PMID: 24684744.

53. Cai X, Tian Y, Wu T, Cao CX, Bu SY, Wang KJ. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. 2014; 16:461–466. PMID: 24556747.

54. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000; 56:302–306. PMID: 10925098.

55. Cheng JY, Ng EM, Ko JS, Chen RY. Physical activity and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007; 19:245–252. PMID: 16929337.

56. Chitaley K, Kupelian V, Subak L, Wessells H. Diabetes, obesity and erectile dysfunction: field overview and research priorities. J Urol. 2009; 182:S45–S50. PMID: 19846136.

57. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291:2978–2984. PMID: 15213209.

58. Kalka D, Domagala Z, Rakowska A, Womperski K, Franke R, Sylwina-Krauz E, et al. Modifiable risk factors for erectile dysfunction: an assessment of the awareness of such factors in patients suffering from ischaemic heart disease. Int J Impot Res. 2016; 28:14–19. PMID: 26631924.

59. Bivalacqua TJ, Rajasekaran M, Champion HC, Wang R, Sikka SC, Kadowitz PJ, et al. The influence of castration on pharmacologically induced penile erection in the cat. J Androl. 1998; 19:551–557. PMID: 9796614.

60. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011; 8:284–293. PMID: 20704642.

61. Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res. 2007; 19:411–417. PMID: 17538639.

62. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010; 7:2572–2582. PMID: 20524974.

63. Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian J Androl. 2016; 18:25–34. PMID: 25761833.

64. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004; 172:658–663. PMID: 15247755.

65. Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012; 157:681–691. PMID: 23165659.

66. Amiaz R, Pope HG Jr, Mahne T, Kelly JF, Brennan BP, Kanayama G, et al. Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial. J Sex Marital Ther. 2011; 37:243–254. PMID: 21707327.

67. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006; 38:61–68. PMID: 16529577.

68. Almehmadi Y, Yassin AA, Nettleship JE, Saad F. Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. Arab J Urol. 2016; 14:31–36. PMID: 26966591.

69. Andrade ES Jr, Clapauch R, Buksman S. Short term testosterone replacement therapy improves libido and body composition. Arq Bras Endocrinol Metabol. 2009; 53:996–1004. PMID: 20126853.

70. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol. 2005; 173:530–532. PMID: 15643239.

71. Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006; 18:400–404. PMID: 16395321.

72. Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male. 2008; 11:146–149. PMID: 18821291.

73. Kim JW, Oh MM, Park MG, Park JY, Bae JH, Kim JJ, et al. Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. Int J Impot Res. 2013; 25:29–33. PMID: 22971615.

74. La Vignera S, Condorelli R, Vicari E, D'Agata R, Calogero A. Original immunophenotype of blood endothelial progenitor cells and microparticles in patients with isolated arterial erectile dysfunction and late onset hypogonadism: effects of androgen replacement therapy. Aging Male. 2011; 14:183–189. PMID: 21271942.

75. Moon DG, Park MG, Lee SW, Park K, Park JK, Kim SW, et al. The efficacy and safety of testosterone undecanoate (Nebido((®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med. 2010; 7:2253–2260. PMID: 20345732.

76. Mulhall JP, Valenzuela R, Aviv N, Parker M. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology. 2004; 63:348–352. discussion 352-3. PMID: 14972487.

77. Okada K, Yamaguchi K, Chiba K, Miyake H, Fujisawa M. Comprehensive evaluation of androgen replacement therapy in aging Japanese men with late-onset hypogonadism. Aging Male. 2014; 17:72–75. PMID: 24533913.

78. Park MG, Yeo JK, Cho DY, Kim JW, Kim JW, Oh MM, et al. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med. 2015; 12:966–974. PMID: 25648342.

79. Pexman-Fieth C, Behre HM, Morales A, Kan-Dobrosky N, Miller MG. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel. Aging Male. 2014; 17:1–11. PMID: 24274081.

80. Rastrelli G, Giovannini L, Calogero AE, Gianfrilli D, Serra E, Pizzocaro A, et al. Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry. J Endocrinol Invest. 2016; 39:695–708. PMID: 27037688.

81. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med. 2007; 4:497–501. PMID: 17367445.

82. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014; 11:1567–1576. PMID: 24712761.

83. Jeong SM, Ham BK, Park MG, Oh MM, Yoon DK, Kim JJ, et al. Effect of testosterone replacement treatment in testosterone deficiency syndrome patients with metabolic syndrome. Korean J Urol. 2011; 52:566–571. PMID: 21927705.

84. Labairu-Huerta L, Padilla-Fernández B, Arrondo-Arrondo JL, Valverde-Martínez LS, Martin-Rodríguez A, Silva-Abuín JM, et al. PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction. Arch Ital Urol Androl. 2015; 87:204–209. PMID: 26428641.

85. Permpongkosol S, Tantirangsee N, Ratana-olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med. 2010; 7:3765–3774. PMID: 20807330.

86. Taniguchi H, Kawa G, Kinoshita H, Matsuda T. Symptomatic change in Japanese hypogonadal patients several years after androgen replacement therapy. Aging Male. 2011; 14:190–194. PMID: 21557686.

87. Tirabassi G, Corona G, Biagioli A, Buldreghini E, delli Muti N, Maggi M, et al. Influence of androgen receptor CAG polymorphism on sexual function recovery after testosterone therapy in late-onset hypogonadism. J Sex Med. 2015; 12:381–388. PMID: 25443437.

88. Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014; 99:3821–3828. PMID: 24978674.

89. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013; 10:1612–1627. PMID: 23551886.

90. Mitkov MD, Aleksandrova IY, Orbetzova MM. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv). 2013; 55:55–63. PMID: 23905488.

91. Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabbà C, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015; 3:1094–1103. PMID: 26447645.

92. Gades NM, Jacobson DJ, McGree ME, St. Sauver JL, Lieber MM, Nehra A, et al. The associations between serum sex hormones, erectile function, and sex drive: the olmsted county study of urinary symptoms and health status among men. J Sex Med. 2008; 5:2209–2220. PMID: 18624959.

93. Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30 week randomized placebo controlled study. BJU Int. 2016; DOI: 10.1111/bju.13516. [Epub].

94. Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014; 11:1577–1592. PMID: 24697970.

95. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016; 374:611–624. PMID: 26886521.

96. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts male aging study. Psychosom Med. 1998; 60:458–465. PMID: 9710291.

97. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009; 29:259–266. PMID: 19440080.

98. Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med. 2008; 5:227–233. PMID: 18173768.

99. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002; 36:1577–1589. PMID: 12243609.